Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia

K. Kuželová, B. Brodská, O. Fuchs, M. Dobrovolná, P. Soukup, P. Cetkovský,

. 2015 ; 10 (5) : e0127637. [pub] 20150520

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020774

Nucleophosmin 1 (NPM1) mutations are frequently found in patients with acute myeloid leukemia (AML) and the newly generated sequences were suggested to induce immune response contributing to the relatively favorable outcome of patients in this AML subset. We hypothesized that if an efficient immune response against mutated nucleophosmin can be induced in vivo, the individuals expressing HLA alleles suitable for presenting NPM-derived peptides should be less prone to developing AML associated with NPM1 mutation. We thus compared HLA class I frequencies in a cohort of patients with mutated NPM1 (63 patients, NPMc+), a cohort of patients with wild-type NPM1 (94 patients, NPMwt) and in normal individuals (large datasets available from Allele Frequency Net Database). Several HLA allelic groups were found to be depleted in NPMc+ patients, but not in NPMwt compared to the normal distribution. The decrease was statistically significant for HLA B(*)07, B(*)18, and B(*)40. Furthermore, statistically significant advantage in the overall survival was found for patients with mutated NPM1 expressing at least one of the depleted allelic groups. The majority of the depleted alleles were predicted to bind potent NPM-derived immunopeptides and, importantly, these peptides were often located in the unmutated part of the protein. Our analysis suggests that individuals expressing specific HLA allelic groups are disposed to develop an efficient anti-AML immune response thanks to aberrant cytoplasmic localization of the mutated NPM protein.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020774
003      
CZ-PrNML
005      
20160722120149.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0127637 $2 doi
024    7_
$a 10.1371/journal.pone.0127637 $2 doi
035    __
$a (PubMed)25992555
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kuželová, Kateřina $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
245    10
$a Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia / $c K. Kuželová, B. Brodská, O. Fuchs, M. Dobrovolná, P. Soukup, P. Cetkovský,
520    9_
$a Nucleophosmin 1 (NPM1) mutations are frequently found in patients with acute myeloid leukemia (AML) and the newly generated sequences were suggested to induce immune response contributing to the relatively favorable outcome of patients in this AML subset. We hypothesized that if an efficient immune response against mutated nucleophosmin can be induced in vivo, the individuals expressing HLA alleles suitable for presenting NPM-derived peptides should be less prone to developing AML associated with NPM1 mutation. We thus compared HLA class I frequencies in a cohort of patients with mutated NPM1 (63 patients, NPMc+), a cohort of patients with wild-type NPM1 (94 patients, NPMwt) and in normal individuals (large datasets available from Allele Frequency Net Database). Several HLA allelic groups were found to be depleted in NPMc+ patients, but not in NPMwt compared to the normal distribution. The decrease was statistically significant for HLA B(*)07, B(*)18, and B(*)40. Furthermore, statistically significant advantage in the overall survival was found for patients with mutated NPM1 expressing at least one of the depleted allelic groups. The majority of the depleted alleles were predicted to bind potent NPM-derived immunopeptides and, importantly, these peptides were often located in the unmutated part of the protein. Our analysis suggests that individuals expressing specific HLA allelic groups are disposed to develop an efficient anti-AML immune response thanks to aberrant cytoplasmic localization of the mutated NPM protein.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a MHC antigeny I. třídy $x imunologie $7 D015395
650    _2
$a lidé $7 D006801
650    12
$a imunita $7 D007109
650    _2
$a akutní myeloidní leukemie $x imunologie $7 D015470
650    _2
$a lidé středního věku $7 D008875
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a mutantní proteiny $x chemie $x metabolismus $7 D050505
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a jaderné proteiny $x chemie $x genetika $x imunologie $7 D009687
650    _2
$a peptidy $x chemie $x imunologie $7 D010455
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brodská, Barbora $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Fuchs, Ota $u Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Dobrovolná, Marie $u Department of HLA, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Soukup, Petr $u Clinical Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Cetkovský, Petr $u Clinical Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 5 (2015), s. e0127637
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25992555 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160722120403 $b ABA008
999    __
$a ok $b bmc $g 1155444 $s 945302
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 5 $d e0127637 $e 20150520 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options